Ipsen nominates Catherine Bradley to its Board of Directors as independent Director

Rhea-AI Summary

Ipsen (ADR: IPSEY) announced the co-optation of Catherine Bradley, CBE, as an independent Director to its Board of Directors, effective immediately, replacing Ms. Witts, who stepped down following the 13 May 2026 Annual General Meeting.

According to Ipsen, Ms. Bradley brings over three decades of investment banking and international financial markets experience and more than ten years as a non-executive director. She has held senior roles at Merrill Lynch, Crédit Suisse and BNP Paribas, and has chaired audit committees at the UK FCA, Aberdeen, Groupe Peugeot and Worldpay.

The Board has appointed her Chair of the Audit Committee and a member of the Compensation Committee. Her mandate will be submitted for ratification at the next Annual Shareholders’ Meeting and, if approved, will run until the 2029 Annual Shareholders’ Meeting, completing Ms. Witts’ term. Ipsen’s Board remains composed of 14 directors, equally split between seven women and seven men, including four independent directors and two employee representatives.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Ipsen appoints Catherine Bradley as independent Director to its Board of Directors

PARIS, FRANCE, 29 JULY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the co-optation of Catherine Bradley, CBE, as an independent Director to its Board of Directors, effective immediately. Ms. Bradley succeeds Ms. Witts who stepped down from the Board following the Annual General Meeting held on 13 May 2026.

With more than 3 decades of experience in investment banking and international financial markets, followed by more than ten years of experience as a non-executive director, Ms. Bradley is a recognized expert in the financial sector and corporate governance. She has held senior leadership positions at leading global financial institutions including Merrill Lynch, Crédit Suisse and BNP Paribas. She also has specific experience in audit committee governance, having chaired the audit committees of the FCA (Financial Conduct Authority) and Aberdeen plc in the United Kingdom, Groupe Peugeot SA in France and Worldpay LLC in the United States. She currently serves as a non-executive director on several boards, notably as Chair of Interactive Investor Limited, as well as at Johnson Electric Holdings Limited in Asia, and easyJet plc, where she chairs the Finance Committee.

Ms. Bradley is a graduate of HEC Paris, where she specialized in finance and international economics. Ms. Bradley is a Commander of the Order of the British Empire (CBE).

The Board of Directors has also appointed Ms. Bradley as Chair of the Audit Committee and a member of the Compensation Committee.

Her appointment will be submitted for ratification at the next Annual Shareholders’ Meeting and, if ratified, will continue for the remainder of Ms. Witts’ term of office, until the Annual Shareholders’ Meeting to be held in 2029.

Following this appointment, Ipsen’s Board of Directors continues to comprise 14 directors, with equal representation of seven women¹ and seven men. The Board includes four independent directors and two employee representatives.

About Ipsen

We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by internal and external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 100 countries.

Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com.

Ipsen Contacts
Investors
Henry Wheeler	henry.wheeler@ipsen.com	+33 7 66 47 11 49
Khalid Deojee	khalid.deojee@ipsen.com	+33 6 66 01 95 26
Media
Sally Bain	sally.bain@ipsen.com	+1 857 320 0517
Anne Liontas	anne.liontas.ext@ipsen.com	+33 7 67 34 72 96

Disclaimers and/or forward-looking statements

The forward-looking statements, objectives and targets contained herein are based on Ipsen’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words ‘believes’, ‘anticipates’ and ‘expects’ and similar expressions are intended to identify forward-looking statements, including Ipsen’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation and risks arising from unexpected regulatory or political changes such as changes in tax regulation and regulations on trade and tariffs, such as protectionist measures, especially in the United States; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen’s patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen’s activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen’s partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen’s business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen’s latest Universal Registration Document, available on ipsen.com.

---

1 Representing 42%, with directors representing employees not taken into account in this calculation, pursuant to article L. 225-18-1 of the French Code of Commerce

Attachment

• PR_BOD Announcement Confidential_2026_Catherine Bradley_EN_2026 07 21

FAQ

What did Ipsen (IPSEY) announce on July 29, 2026 regarding its Board of Directors?

Ipsen announced the co-optation of Catherine Bradley, CBE, as an independent Director to its Board, effective immediately. According to Ipsen, she replaces Ms. Witts, who stepped down after the May 13, 2026 Annual General Meeting, and will stand for ratification at the next shareholders’ meeting.

Who is Catherine Bradley, newly appointed independent Director at Ipsen (IPSEY)?

Catherine Bradley is a finance and corporate governance expert with over three decades in investment banking and more than ten years as a non-executive director. According to Ipsen, she has held senior roles at Merrill Lynch, Crédit Suisse and BNP Paribas and chaired multiple international audit committees.

What roles will Catherine Bradley hold on Ipsen’s Board committees?

Catherine Bradley will serve as Chair of Ipsen’s Audit Committee and as a member of the Compensation Committee. According to Ipsen, she brings extensive prior audit committee chair experience from the FCA, Aberdeen, Groupe Peugeot and Worldpay, strengthening the group’s financial oversight and governance expertise.

How long will Catherine Bradley’s term on the Ipsen (IPSEY) Board last if ratified?

If ratified at the next Annual Shareholders’ Meeting, Catherine Bradley’s mandate will run until the 2029 Annual Shareholders’ Meeting. According to Ipsen, she is completing the remainder of Ms. Witts’ original term of office rather than starting a new full-length mandate.

How does Catherine Bradley’s appointment affect Ipsen’s Board composition in 2026?

Following her appointment, Ipsen’s Board continues to comprise 14 directors, with seven women and seven men. According to Ipsen, the Board also includes four independent directors and two employee representatives, maintaining its existing size while reinforcing independent financial and governance expertise.

What is Catherine Bradley’s professional background relevant to Ipsen’s Audit Committee?

Catherine Bradley has deep experience in financial markets and audit governance, including senior roles at major global banks. According to Ipsen, she has chaired audit committees at the UK FCA, Aberdeen, Groupe Peugeot and Worldpay, experience directly aligned with chairing Ipsen’s Audit Committee.

What are Ipsen’s main business areas and listing details for investors in IPSEY?

Ipsen focuses on biopharmaceutical medicines in Oncology, Rare Disease and Neuroscience, serving patients in over 100 countries. According to Ipsen, its shares trade on Euronext Paris (IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program under the symbol IPSEY.